{"classes":[{"categories":[{"measurements":[{"comment":"Data was not estimable due to insufficient number of participants who had the event.","groupId":"OG000","lowerLimit":"11.66","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"8.12","upperLimit":"8.54","value":"8.28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"546"},{"groupId":"OG001","value":"542"}],"units":"Participants"}],"description":"The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\\>=) 2 new lesions compared to baseline was observed in less than (\\<) 12 weeks from randomization and was confirmed by a second bone scan taken \\>=6 weeks later showing \\>=2 additional new lesions (a total of \\>=4 new lesions compared to baseline), b) the first bone scan with \\>=2 new lesions compared to baseline was observed in \\>=12 weeks from randomization and the new lesions were verified on the next bone scan \\>=6 weeks later (a total of \\>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG000","title":"Abiraterone Acetate + Prednisone (AAP)"},{"description":"Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)","title":"Radiographic Progression-free Survival (rPFS)","type":"PRIMARY","unitOfMeasure":"Months"}